Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hematopoietic growth factors]

A M Stoppa1, D Blaise, P Viens

  • 1Institut Paoli Calmettes, Marseille.

Presse Medicale (Paris, France : 1983)
|March 20, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

Foliar efficacy of phosphorous formulations for rainfed cotton with graded levels.

Scientific reports·2026
Same author

Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.

Bone marrow transplantation·2024
Same author

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

Bone marrow transplantation·2023
Same author

Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic.

Bone marrow transplantation·2021
Same author

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Hematopoietic growth factors, including G-CSF, GM-CSF, EPO, and IL-3, are key glycoproteins that regulate blood cell production. These factors effectively treat infections, anemia, and thrombocytopenia in various medical conditions.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Hematology

Context:

  • Hematopoietic growth factors are crucial glycoproteins regulating blood cell development.
  • These factors interact with specific cell membrane receptors.
  • Their therapeutic applications address various hematological disorders.

Purpose:

  • To summarize the roles and therapeutic benefits of hematopoietic growth factors.
  • To highlight their impact on managing chemotherapy-induced side effects and chronic diseases.

Summary:

  • Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) mitigate infections in neutropenia caused by chemotherapy for onco-hematological malignancies.
  • Erythropoietin (EPO) corrects anemia in chronic renal failure and chemotherapy-associated anemia.

Related Experiment Videos

  • Interleukin-3 (IL-3) shows potential in managing thrombocytopenia by influencing platelet production.

    • Impact:

    • These growth factors significantly reduce treatment morbidity and expand therapeutic options.
    • They improve patient outcomes in oncology, nephrology, and hematology.
    • Understanding these factors enhances the management of hematological conditions and side effects of cancer therapy.